Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aramchol Phase IIb in NASH
2014-003107-29Phase 2Completed
- Sponsor
- Galmed Pharmaceuticals
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aramchol in metabolic dysfunction-associated steatohepatitis (MASH) (3 arms), sponsored by Galmed Pharmaceuticals. Primary endpoint: Percent change from baseline to end of study in liver triglycerides ratio. Started Jan 2015; status: completed.
02
Drugs
aramchol
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2014-003107-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003107-29.